drugset / Trial / NCT06832566

Ramadan Fasting Outcomes in Patients With Secondary Adrenal Insufficiency Before and After the Treatment of Hypotension.

NCT06832566

Phase 4 Not yet recruiting 20 enrolled Hopital La Rabta
NaSingle-groupOpen-labelTreatment

Summary

Intermittent fasting in patients with adrenal insufficiency is associated with an increased risk of complications, such as dehydration. A recent study showed that nearly half the patients had hypotension before the fasting month and half had signs of dehydration during fasting. So, we are planning to carry out this prospective interventional study in patients with SAI and hypotension to evaluate the effect of treating hypotension with fludrocortisone on the risk of complications during fasting. Patients with secondary adrenal insufficiency and hypotension and who are willing to fast during Ramadan 2025 will be included. Before Ramadan, they will be treated with fludrocortisone at a dose of 50micg/day. The occurrence of complications and the number of fasted days during Ramadan 2025 will be reported and compared with those of Ramadan 2023.

Timeline

Start
2025-02-15
Primary completion
2025-04-15
Completion
2025-04-15

Publications

  • Results Chihaoui et al, Nutrition, 2025; https://doi.org/10.1016/j.nut.2025.112688

Drugs

EvaluationDrugModalityDoseRoute
Subject Fludrocortisone Other / unclassified 0.05 mg